Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Up 6.0% in January

Keros Therapeutics, Inc. (NASDAQ:KROS) was the recipient of a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 4,260,000 shares, a growth of 6.0% from the January 15th total of 4,020,000 shares. Based on an average daily volume of 1,500,000 shares, the days-to-cover ratio is currently 2.8 days.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC grew its holdings in shares of Keros Therapeutics by 6.8% in the 3rd quarter. Geode Capital Management LLC now owns 725,621 shares of the company’s stock worth $42,146,000 after purchasing an additional 46,041 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in Keros Therapeutics by 14.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 260,120 shares of the company’s stock worth $15,105,000 after buying an additional 32,492 shares during the last quarter. Barclays PLC increased its holdings in shares of Keros Therapeutics by 140.1% during the third quarter. Barclays PLC now owns 60,014 shares of the company’s stock worth $3,484,000 after buying an additional 35,022 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Keros Therapeutics in the fourth quarter valued at approximately $388,000. Finally, Intech Investment Management LLC acquired a new position in shares of Keros Therapeutics in the 3rd quarter worth approximately $603,000. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

KROS has been the subject of a number of analyst reports. Guggenheim restated a “neutral” rating on shares of Keros Therapeutics in a research note on Friday, January 17th. Wells Fargo & Company boosted their target price on shares of Keros Therapeutics from $88.00 to $111.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. HC Wainwright reduced their price target on shares of Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating for the company in a report on Friday, December 13th. William Blair lowered shares of Keros Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Thursday, December 12th. Finally, Scotiabank decreased their target price on Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating on the stock in a research report on Thursday, January 16th. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Keros Therapeutics has an average rating of “Moderate Buy” and an average price target of $52.56.

Keros Therapeutics Price Performance

Shares of KROS traded up $0.17 during mid-day trading on Monday, reaching $10.32. The company had a trading volume of 966,902 shares, compared to its average volume of 2,180,866. The company has a market capitalization of $418.06 million, a P/E ratio of -1.98 and a beta of 1.39. Keros Therapeutics has a twelve month low of $9.77 and a twelve month high of $73.00. The company’s 50-day moving average is $16.91 and its 200-day moving average is $42.00.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.